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The potential anticancer agent 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinolinecarbox-
amide (PK11195), a translocator protein (18KDa) (TSPO) ligand, facilitates the induc-
tion of cell death by a variety of cytotoxic and chemotherapeutic agents. Primary
chronic lymphocytic leukemia (CLL) cells overexpress TSPO. The aim of this study was
to examine the effects of PK11195 on CLL cells.
Design and Methods
Using cytometric analysis, we studied the cytotoxic effects of PK11195 on peripheral
B and T lymphocytes from patients with CLL and from healthy donors. Western blot
and cytometric analyses were used to study the mitochondrial effects of PK11195 on
CLL cells. Moreover, we analyzed the cytotoxic effect of PK11195 in patients’ cells
with mutated p53 or ATM. 
Results
PK11195 induces apoptosis and had additive effects with chemotherapeutic drugs in
primary CLL cells. Other TSPO ligands such as RO 5-4864 and FGIN-1-27 also induce
apoptosis in CLL cells. PK11195 induces mitochondrial depolarization and cyto-
chrome c release upstream of caspase activation, and dithiocyana-tostilbene-2,2-
disulfonic acid (DIDS), a voltage-dependent anion channel (VDAC) inhibitor, inhibits
PK11195-induced apoptosis, demonstrating a direct involvement of mitochondria.
CLL cells and normal B cells are more sensitive than T cells to PK11195-induced
apoptosis. Interestingly, PK11195 induced apoptosis in CLL cells irrespective of their
p53 or ATM status.
Interpretation and Conclusions
These results suggest that PK11195 alone or in combination with chemotherapeutic
drugs might be a new therapeutic option for the treatment of CLL.
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ABSTRACT
Chronic lymphocytic leukemia (CLL) ischaracterized by the accumulation ofmature malignant CD5+ B lympho-
cytes.1 Although many drugs have been used
in the therapy of CLL, at present there is no
curative therapy, and the search for new can-
didate drugs for future treatment of CLL is an
active area of research. Most drugs currently
used in CLL therapy induce apoptosis of the
leukemic cells, at least partially, through acti-
vation of the p53 pathway.2-7 The mechanisms
of resistance to such drugs include inactivation
of p53, which is mutated in 5-10% of CLL
cases at diagnosis, but in nearly 30% of
chemotherapy-resistant cases of CLL.2-4,8
Hence, new therapies that overcome these
defects by acting independently of p53 are of
great interest.9
The potential anticancer agent 1-(2-chloro-
phenyl-N-methylpropyl)-3-isoquinolinecar-
boxamide (PK11195) facilitates the induction
of cell death by a variety of agents including
Fas ligand (FasL) and chemotherapeutic
drugs.10-16 Furthermore, in some cell types,
PK11195 alone is able to induce apoptosis.16-21
Importantly, PK11195 chemosensitizes pri-
mary human acute myeloid leukemia and
multiple myeloma cells.22-24 PK11195 was ini-
 
tially described as a ligand for peripheral benzodiazepine
receptor (PBR),25 whose new proposed name is translocator
protein (18 KDa) (TSPO).26 TSPO is a transmembrane pro-
tein that is located mainly in the outer mitochondrial
membrane, but is also expressed in other subcellular com-
partments. TSPO is associated with the regulation of cho-
lesterol transport, the synthesis of steroid hormones, por-
phyrin transport, heme synthesis, apoptosis and cell prolif-
eration.26 Other chemically unrelated TSPO ligands induce
apoptosis in different cell types,15,17,19-21 indicating a TSPO-
dependent mechanism; however, TSPO-independent
mechanisms have been proposed to inhibit cell prolifera-
tion or sensitize cells to apoptosis.24,27,28 It has been report-
ed that PK11195 induces apoptosis by altering the mito-
chondrial permeability transition.10,11 Interestingly, in a vari-
ety of systems, PK11195 can reduce or abrogate the anti-
apoptotic effect of BCL-2-like proteins, including BCL-2
and BCL-XL.22,29 Since primary CLL cells overexpress
TSPO30 and BCL-2,31,32 we decided to examine the effects of
PK11195 on CLL cells.
Design and Methods
Samples, patients with CLL, healthy donors and cell
isolation
Samples from patients with CLL (Table 1) or healthy
donors were studied. Most of the patients had not been
treated previously (patients number 1, 13, 17, 23, 24, 27, 28
and 33 were, however, treated). The patient number in
Table 1 corresponds to the patient number in the figures.
CLL was diagnosed according to standard clinical and lab-
oratory criteria. Blood samples were obtained from the
Hospital de Bellvitge, Barcelona, Spain. Written informed
consent was obtained from all patients in accordance with
the Hospital de Bellvitge Ethical Committee. Mononuclear
cells from peripheral blood samples were isolated by cen-
trifugation on a Ficoll-Hypaque (Seromed, Berlin, Ger-
many) gradient and cryopreserved in liquid nitrogen in the
presence of 10% dimethyl sulfoxide (DMSO). 
Multiplex ligation-dependent probe amplification (MLPA)
for genomic alterations and reverse transcriptase (RT)-
MLPA
DNA was isolated and analyzed by MLPA using SALSA
MLPA kits P037 and P038 from MRC-Holland (Amsterdam,
The Netherlands). These kits were used to determine the
loss of p53 (17p13; 8 probes), the RB1/DLEU/MIR15-16
region on 13q14 (12 probes) and the ATM gene on 11q23 (7
probes) in DNA samples obtained from CLL cells. RNA was
isolated from cultured cells by the RNeasy Micro kit
(Qiagen Inc., Valencia, CA, USA) according to the manufac-
turer’s protocol. RNA was analyzed by RT-MLPA using the
SALSA MLPA kit R011 Apoptosis mRNA from MRC-
Holland (Amsterdam, The Netherlands) for the simultane-
ous detection of 38 mRNA molecules.7,33
Analysis of apoptosis by flow cytometry
Apoptosis was assessed by exposure of phos-
phatidylserine and membrane integrity. This was deter-
mined by annexin V-fluorescein isothiocyanate (FITC),
propidium iodide (PI) double staining, and flow cytomet-
ric analysis using FACSCalibur and CellQuest software
(Becton Dickinson, Mountain View, CA, USA), as
described previously.34 Cell viability was measured as the
percentage of annexin V and PI double-negative cells. To
A.F. Santidrián et al. 
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Table 1. Characteristics of the patients with chronic lymphocytic
leukemia.
Patient Age/ WBC Lymphocytes CD38 ZAP70 Genomic* Binet/ PK50† F/T 
No. sex (%) (%) (%) alterations Rai‡ (%) (%)
1 79/M 30 91 <20 <20 del 13q° B/2 70 F
2 76/F 38 79 <20 48 del 13q C/4 71/75 F/T
3 63/M 84 91 <20 43 del 13q° A/0 83 F
4 65/M 19 77 64 53 tris 12° B/2 54 F
5 70/M 70 79 24 86 del 11q, C/4 41 T
del 13q
6 49/F 31 ND <20 <20 ND A/1 48 F
7 75/F 91 ND <20 <20 del 13q° B/1 8 F
8 78/F 41 97 83 44 del 11q, B/1 84 T
del 13q
9 77/M 23 81 ND 50 ND A/0 11 F
10 54/F 23 79 71 <20 normal C/4 64 T
11 73/M 41 89 <20 22 del 13q B/2 77 F
12 71/M 97 97 51 48 del 11q, A/0 80 F
del 13q
13 66/M 30 ND 66 ND normal° C/4 64 F
14 69/F 53 95 <20 28 ND C/4 72 F
15 59/F 46 ND <20 ND del 13q B/1 78 T
16 70/M 110 ND <20 26 normal# C/3 42 T
17 70/M 83 98 63 82 del 13q° C/3 61 F
18 69/M 81 90 <20 <20 del 13q° A/0 24 F
19 71/F 45 69 ND nd ND A/0 51 F
20 67/F 110 93 41 42 del 11q, C/4 39 T
tris 12
21 84/F 91 88 71 <20 ND C/3 60 F
22 84/F 69 94 <20 <20 ND A/0 51 F
23 67/M 50 94 <20 ND ND A/0 8 F
24 70/M 118 99 93 39 del 13q, C/4 56/48 F/T
del 17p
25 82/M 40 87 ND <20 del 13q A/0 63 F
26 76/M 24 81 <20 <20 ND A/1 84 F
27 80/M 22 50 >20 <20 tris 12# C/3 17 F
28 79/M 27 86 <20 <20 del 13q# A/1 70 F
29 65/M 27 81 <20 <20 del 13q A/0 47 F
30 40/M 81 90 <20 46 del 13q B/2 61 F
31 74/M 31 88 92 <20 ND C/4 45 T
32 69/M 25 85 <20 <20 ND C/4 38 T
33 80/F 66 96 <20 <20 del 13q C/4 51 T
34 81/M 53 81 <20 <20 normal# A/0 47 T
35 62/F 46 ND <20 79 normal C/4 59 T
36 51/M 128 100 <20 <20 ND C/4 64 F
37 65/M 61 90 ND <20 del11q° B/1 39 T
38 73/M 32 82 <20 <20 del11q# C/4 54 T
39 82/M 28 81 57 <20 del 11q° A/1 60 T
40 47/M 36 93 30 <20 del 11q 13q#B/2 34 T
WBC indicates white blood cell count (109/L); F: female; M: male; del: deletion;
and ND: not determined; F: fresh cells; T: frozen-thawed cells. ZAP-70 was
determined by flow cytometry in fixed cells with a conjugated antibody
(Alexa-Fluor 488) (Caltag Laboratories, Burlingame, CA, USA). A sample was 
considered negative when the expression was less than 20%.
*Genomic alterations were determined by fluorescent in situ hybridization (FISH)
except for °determined by MLPA or #determined by MLPA and FISH. ‡According 
to Binet/Rai’s classification. †Cell viability after 50 µM PK11195 treatment for 24
hours. Control viability was normalized to 100%. 
analyze apoptosis in T cells and B cells from the samples,
5×105 cells were incubated for 24 or 48 hours with the
indicated factors. Cells were then washed in phosphate-
buffered saline (PBS), and incubated in 50 µL annexin-
binding buffer with allophycocyanin (APC)–conjugated
anti-CD3 and phycoerythrin (PE)–conjugated anti-CD19
from Becton Dickinson (Franklin Lakes, NJ, USA) for 10
minutes in the dark. Cells were then diluted with annex-
in-binding buffer to a volume of 150 µL and incubated
with 1 µL annexin V–FITC for 15 minutes in the dark.
Cells were analyzed using the FACScalibur and CellQuest
software.
Cytochrome c release measurements
Release of cytochrome c from mitochondria into the
cytosol was measured by western blot as previously
described35 with some modifications. Cells (25×106) were
harvested, washed once with ice-cold PBS and gently lysed
for 30 seconds in 80 µL ice-cold lysis buffer (250 mM
sucrose, 1 mM EDTA, 0.05% digitonin, 25 mM Tris, pH
6.8, 1 mM dithiothreitol, 1 µg/mL leupeptin, 1 µg/mL pep-
statin, 1 µg/mL aprotinin, 1 mM benzamidine, and 0.1
mM phenylmethylsulfonyl fluoride). Lysates were cen-
trifuged at 12,000×g at 4°C for 3 minutes to obtain the
supernatants (cytosolic extracts free of mitochondria) and
the pellets (the fraction containing the mitochondria).
Supernatants (50 µg) were electrophoresed on a 15% poly-
acrylamide gel and then analyzed by western blot using
anti-cytochrome c antibody (7H8.2C12, from Pharmingen,
San Diego, CA, USA) and an electrochemiluminescence
system, as described in online supplementary data.
Statistical analysis
Results are shown as the mean ± standard deviation
(SD) of values obtained in independent experiments. The
paired Student’s t test was used to compare differences
between paired samples. Data were analyzed using the
SPSS 11.5 software package (Chicago, IL, USA). Additive
and synergistic effects were analyzed using the fractional
product method.36
Results
PK11195 and other TSPO ligands induce apoptosis in
CLL cells
As FasL does not induce apoptosis in CLL cells37 we
first examined whether PK11195 reverses this resistance
in CLL cells, but PK11195 was not able to do so (Figure
1A). However, when combined with the chemothera-
peutic drugs, dexamethasone, doxorubicin, chlorambu-
cil, fludarabine and mafosfamide, PK11195 had an addi-
tive effect  in inducing apoptosis in CLL cells (Figures 1B,
1C and 1D). It is interesting to note that 50 µM PK11195
alone induced apoptosis in most of the samples analyzed
in Figure 1. Thus, we studied the effect of several doses
of PK11195 on the viability of CLL cells. Although there
was heterogeneity in the sensitivity of CLL cells,
PK11195 induced apoptosis in all the samples analyzed
in a dose-dependent manner (Figure 2A) and the IC50 was
60±21 µM (n=29) at 24 hours. The viability after incuba-
tion for 24 hours with 50 µM PK11195 decreased from
66±18% to 38±21% (n=33), and with 100 µM PK11195
it decreased from 71±16% to 16±13% (n=19). Fresh or
frozen-thawed CLL cells showed the same sensitivity to
PK11195 (Table 1). The average of the effect of 50 µM
PK11195 was 54±21% for fresh cells and 53±15% for
thawed cells. Furthermore, PK11195 had the same effect
on viability of fresh or frozen-thawed CLL cells from the
same sample (patients 2 and 24, Table 1). PK11195
induced apoptosis independently of sex, ZAP70 or CD38
status (Table 1).  Next, we analyzed whether other com-
pounds described as TSPO ligands could induce apopto-
sis in CLL cells. Thus, CLL cells were incubated for 24
hours with PK11195 and the TSPO ligands RO 5-4864
and FGIN-1-2726 in a range of concentrations (12.5-100
µM). Similarly to PK11195, both RO 5-4864 and FGIN-1-
27 induced apoptosis in a dose-dependent manner and
their IC50 were 83±18 µM and 88±31 µM, respectively
(n=9) (Figure 2B). Moreover, PK11195 had a synergistic
effect with regards to induction of apoptosis in CLL cells
when combined with the other TSPO ligands, RO 5-
4864 and FGIN-1-27 (Figure 2C).
PK11195 induces apoptosis in CLL cells
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Figure 1. Additive effect of PK11195 and chemotherapeutic drugs.
Cells from four different CLL patients were treated without (open
bars) or with (filled bars) 50 µM PK11195 and with 100 ng/mL FasL
(A), or with 10 µM dexamethasone (Dexa) or 0.4 µM doxorubicin
(Doxo) for 24 hours (B), or with 10 µM chlorambucil (Chlo) for 48
hours (C), or with 3 µM fludarabine (Fluda) or 5 µM mafosfamide
(Mafos) or both for 48 hours (D). Viability was measured by analysis
of phosphatidylserine exposure and PI uptake as described in the
Design and Methods section, and is expressed as the mean value ±
SD of the percentage of nonapoptotic cells. **p<0.05, *p<0.1,
PK11195 treated cells versus PK11195 untreated cells. ‡p< 0.05,
dexamethasone or mafosfamide plus fludarabine treated cells versus




































































Characterization of PK11195-induced apoptosis in CLL
cells: loss of mitochondrial membrane potential and
cytochrome c release precede caspase activation
The effect of PK11195 on the loss of mitochondrial
membrane potential (∆ψm) and cytochrome c release was
analyzed in CLL cells. First, we analyzed the effect of 50
µM PK11195 on ∆ψm using the JC-1 dye. PK11195 induced
apoptosis (Figure 3A), and decreased ∆ψm (Figure 3B) at 6
hours. The caspase inhibitor Z-VAD.fmk did not inhibit
loss of ∆ψm but did inhibit PK11195-induced apoptosis,
indicating that early loss of ∆ψm is caspase-independent.
Furthermore, to analyze the involvement of cytochrome c
release in PK11195-induced apoptosis, cytosolic fractions
were obtained and the presence of cytochrome c was ana-
lyzed by western blotting. Treatment with 50 µM
PK11195 for 6 hours produced an increase in cytochrome c
in the cytosolic fraction of CLL cells from two different
representative patients (Figure 3C), demonstrating that
PK11195 induced cytochrome c release. Z-VAD.fmk did
not inhibit PK11195-induced cytochrome c accumulation
in the cytosol. Furthermore, PK11195 induced cleavage
and activation of caspase-9 at 9 hours (Figure 3D). These
results demonstrate that the mitochondrial effects of
PK11195 are caspase-independent and precede the activa-
tion of caspases. 
To study the mechanism involved in PK11195-induced
cytochrome c release, we used RT-MLPA to analyze
changes in the expression of genes involved in the control
of apoptosis.7,33 PK11195 treatment for 3 and 6 hours did
not modify the expression of any of the genes of the BCL-
2 family analyzed (data not shown). Furthermore, treatment
with PK11195 for 3 or 6 hours neither increased the levels
of the pro-apoptotic proteins BIM, PUMA, and BMF, nor
decreased the levels of the anti-apoptotic proteins MCL-1,
BCL-XL and BCL-2 (Figure 4A). Furthermore, treatment
with PK11195 did not change the levels of the pro-apop-
A.F. Santidrián et al. 
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Figure 2. Cytotoxic effect of PK11195 and other TSPO ligands on CLL
cells. (A) Cells from 12 CLL patients were incubated with the indicat-
ed doses of PK11195 for 24 hours. (B) Dose-response of the cytotox-
ic effect of PK11195, RO 5-4864 or FGIN-1-27. Cells from nine CLL
patients were incubated with several doses of the drugs for 24 hours.
**p<0.01; *p<0.05 treated cells versus control cells. (C) Cells from
five CLL patients were treated without (open bars) or with (filled bars)
50 µM PK11195 and with 50 µM RO 5-4864 or with 50 µM FGIN-1-
27.*p<0.01, PK11195 treated cells versus PK11195 untreated cells.
‡p<0.01 FGIN-1-27 treated cells versus control cells. Data are shown
as the mean value ± SD. Viability was measured by analysis of phos-
phatidylserine exposure and PI uptake as described in the Design and
Methods section and it is expressed as the percentage of non-apop-
totic cells. 
Figure 3. Caspase-independent mitochondrial effects of PK11195 on
CLL cells. Cells from CLL patients were incubated without (Control)
or with (PK) 50 µM PK11195 and in the presence (filled bars) or in
the absence (open bars) of 200 µM Z-VAD.fmk for 6 hours. (A) Cell
viability was quantified by annexin V binding at 6 hours and is
expressed as the percentage of non-apoptotic cells ± SD (n=5).
Control viability was normalized to 100%. *p<0.05 treated cells ver-
sus untreated cells. (B) Changes in ∆ψm were measured by staining
with JC-1. The loss in ∆ψm is seen as a shift to lower JC-1 red fluores-
cence (FL-2) and is expressed as the percentage of high FL-2 cells.
Data are shown as the mean value ± SD of five CLL samples. (C)
Effect of Z-VAD.fmk on PK11195-induced cytochrome c release into
the cytosol. Cells were pre-incubated without or with 200 µM Z-
VAD.fmk for 30 minutes and then treated with 50 µM PK11195 for
6 hours. Cytochrome c and ERK 1/2, which was used as a control of
protein loading in cytosolic cell extracts, were analyzed by western
blot as described in the Design and Methods section. Cell viability at
24 hours is also shown. (D) CLL cells were treated with 50 µM
PK11195 for 0, 6, 9 and 12 hours. Cells were lysed and cleaved cas-
pase 9 and BCL-2 were analyzed by western blot as described in the
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totic protein BAX and induced an increase in the levels of
MCL-1 protein in most of the samples analyzed (Figure 4A
and 4B). Moreover, inhibition of cAMP-dependent protein
kinase (PKA) or JNK with the specific inhibitors (H89 or
SP600125, respectively) did not affect PK11195-induced
apoptosis. Interestingly, DIDS, a voltage-dependent anion
channel (VDAC) inhibitor,38 reduced the pro-apoptotic
activity of PK11195 in CLL cells (Figure 4C). As a control,
DIDS did not inhibit apoptosis induced by fludarabine or
doxorubicin (data not shown).
Differential effect of PK11195 on B and T cells from
patients with CLL and healthy donor
Next, we analyzed the sensitivity of normal B and T cells
to apoptosis induced by PK11195. The number of apoptot-
ic CD3+ T cells was measured in blood samples from four
CLL patients and four healthy donors exposed to several
doses of PK11195, ranging from 12.5 µM to 100 µM, for 24
hours (Figure 5A). Treatment with 50 µM PK11195
reduced the percentage of viable CLL CD19+ B cells to
46±7% and the IC50 was 47±2 µM. In contrast, under the
same treatment the percentage of viable T cells from the
same samples was 95±4% with an IC50 of 87±8 µM.
Similar results were obtained with cells obtained from
healthy donors such that 50 µM PK11195 reduced the via-
bility of B cells to 42±3%, with an IC50 of 49±4 µM, while
the viability of T cells was 98±6% with an IC50 of 82±8
µM. At doses of PK11195 higher than 50 µM, T cells from
CLL patients and healthy donors showed sensitivity to
apoptosis although to a lesser extent than B cells. These
dose-response experiments show that B cells are more sen-
sitive than T cells to PK11195-induced apoptosis. Similarly,
T cells are more resistant than B cells from CLL samples to
RO 5-4864- and FGIN-1-27-induced apoptosis (Figure 5B). 
PK11195 induces apoptosis irrespective of p53 and ATM
status in CLL cells
To study the role of p53 in PK11195-induced apoptosis
we analyzed the effect of this compound on p53 protein
levels (Figure 6A). The patients with mutated p53 (patients
24 and 33) or altered expression were described previous-
ly.7 Patient 24 has a frame-shift mutation in one allele
(nucleotide deletion in codon 272) and a 17p deletion in the
other allele in 86% of cells from peripheral blood leuko-
cyte (PBL) samples, and patient 33 has the M246V muta-
Figure 4. Characterization of PK11195-induced apoptosis in CLL
cells. (A) Cells from a representative patient were treated with 50
µM PK11195 for 0, 3, and 6 hours. Cells were lysed and analyzed by
western blot as described in the Design and Methods section. Total
levels of BIM, PUMA, BAX, MCL-1, BCL-XL, and BCL-2 are shown. (B)
Cells from four different patients were treated with 50 µM PK11195
for 6 hours. Cells were lysed and analyzed by western blot as
described in the Design and Methods section. Total levels of BAX,
MCL-1, and BCL-2 are shown. (C) Cells from several CLL patients
were preincubated with 10 µM H89 (n=4), or with 10 µM SP600125
(SP) (n = 3), or with 200 µM DIDS (n=5) for 30 minutes prior to expo-
sure to 50 µM PK11195 (PK) for 24 hours. Cell viability was quanti-
fied by annexin V binding and is expressed as the percentage of non-
apoptotic cells ± SD. Viability of untreated cells was normalized to
100%. *p<0.05 treated cells versus untreated cells
Figure 5. Differential effect of TSPO ligands on B and T cells. (A)
Dose-response of the cytotoxic effect of PK11195 on CD3-/CD19+ B
cells from four CLL patients (I), CD3–/CD19+ B cells from three
healthy donors (L) and CD3+/CD19– T cells from four CLL and three
healthy donors (o). Cells were incubated with the indicated doses of
PK11195 for 24 hours. (B) Cells from three CLL patients were incu-
bated with the indicated doses of RO 5-4864 (O, o) or FGIN-1-27 (L,
l) for 24 hours. Viability was measured as nonapoptotic CD3+/CD19–
T cells (I,L) or CD3–/CD19+ B cells (o, l) as described in the Design
and Methods section and expressed as the percentage of the viabil-
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tion, which has been described to interfere with wild type
p53.39 When CLL cells were incubated with 50 µM
PK11195 there was no change in p53 levels (Figure 6A). As
a control of p53 activation we used doxorubicin (0.8 µM),
which induced apoptosis and p53 protein accumulation in
wild type p53 cells (from patients 16 and 34) but not in
mutated p53 cells (from patients 24 and 33). In patient 24,
doxorubicin induced a low accumulation of mutated p53.
Interestingly, PK11195 induced apoptosis in CLL cells with
mutated p53 (Figure 6A). Furthermore, chemotherapeutic
drugs that activate p53 did not increase the apoptotic effect
of PK11195 in p53-mutated samples (data not shown).
Next, we analyzed the effect of PK11195 on CLL cells
with ATM alterations. ATM expression was analyzed by
western blotting in several patients with and without 11q
deletion (Figure 6B). We found loss of ATM expression in
three patients with an 11q deletion (patients 5, 8 and 39).
Patients 5 and 8 have the 11q deletion in one allele in 90%
and 86% of cells from PBL samples, respectively. The low
expression of ATM likely corresponds to the percentage of
contaminating normal cells. PK11195 induced apoptosis in
CLL cells with 11q deletion irrespectively of the expression
of ATM protein (Figure 6C). 
Discussion
In this work we show that the potential anticancer agent
PK11195 induces apoptosis in primary CLL cells. Several
targets for the induction of apoptosis by PK11195 have
been suggested. The best known target of PK11195 is
TSPO,25 which is overexpressed in CLL cells.30 Other TSPO
ligands such as RO 5-4864 and FGIN-1-27 also induce
apoptosis in primary CLL cells. However, the role of TSPO
in PK11195-induced apoptosis is controversial. PK11195
binds to TSPO in vivo at nanomolar concentrations,25
although PK11195 induces apoptosis at much higher con-
centrations (50-100 µM). Furthermore, siRNA experiments
demonstrate that TSPO is not necessary to inhibit cell pro-
liferation27 or sensitize cells to apoptosis.28 Multidrug resist-
ance (MDR) has been proposed as a PK11195 target to sen-
sitize cells to apoptosis and could explain the synergism
between PK11195 and other chemotherapeutic drugs that
are transported by MDR proteins.24 PK11195 inhibits MDR
in CLL cells (data not shown) and this could contribute to the
additive effect of PK11195 and chemotherapeutic drugs.
However, PK11195 was able to induce apoptosis alone in
CLL, whereas it is not clear how inhibition of MDR could
induce apoptosis in the absence of other drugs.
Furthermore, cyclosporine A inhibits MDR without affect-
ing the viability of CLL cells (data not shown). Thus, there is
no correlation between inhibition of MDR and induction
of apoptosis by PK11195 alone. Taken together, these
results indicate that the apoptotic activity of PK11195 can-
not be attributed to its inhibitory effect on MDR. 
Moreover, PK11195 was described as a phosphodi-
esterase (PDE) inhibitor in vitro.40 PDE inhibitors induce
cyclic AMP (cAMP) levels and have been described as
apoptotic inducers in CLL cells.41 However, H89, a cAMP-
dependent protein kinase inhibitor did not inhibit
PK11195-induced apoptosis, indicating that PK11195
induces apoptosis in CLL cells through a different mecha-
nism. JNK has also been involved in the induction of apop-
tosis by the combination of PK11195 and bortezomib,23
but in CLL cells inhibition of JNK did not protect from
PK11195-induced apoptosis.
We have shown that PK11195 induces caspase-depend-
ent apoptosis in CLL cells. Furthermore, PK11195 has
Figure 6. PK11195 induces apoptosis independently of p53 and
ATM in CLL cells. (A) PK11195 does not induce p53 stabilization and
accumulation in CLL cells. Cells from two CLL patients with wild-type
p53 (patients 16 and 34) and two with mutant p53 (patients 24 and
33) were untreated (C), or treated with 50 µM PK11195 (PK), or 0.8
µM doxorubicin (D) for 24 hours. Cells were lysed and analyzed by
western blot as described in the Design and Methods section. Total
levels of p53, and BCL-2 were analyzed. Viability was measured by
analysis of phosphatidylserine exposure and PI uptake as described
in the Design and Methods section and is expressed as the percent-
age of non-apoptotic cells. (B) Analysis of ATM expression in cells
from CLL patients without genomic alterations (WT) (patients 10, 34
and 35), or with 11q deletion (del 11q) (patients 5, 8, 20, 37, 38, 39
and 40). mTOR was used as a control of protein loading. (C) Cells
without genomic alteration and with ATM expression (WT) (patients
10, 34 and 35), or cells with 11q deletion (del 11q) and without ATM
expression (ATM– (patients 5, 8,and 39), or with ATM expression
(ATM+) (patients 20, 37, 38 and 40) were incubated with (filled bars)
or without (open bars) 50 µM PK11195 for 24 hours. Viability was
measured by analysis of phosphatidylserine exposure and PI uptake
as described in the Design and Methods section, and is expressed as
the mean value ± SD of the percentage of non-apoptotic cells.
Viability of untreated cells was normalized to 100%. *p<0.05 treat-
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effects in mitochondria upstream of caspase activation, as
a caspase inhibitor was not able to inhibit the mitochondr-
ial effects induced by PK11195, such as depolarization and
cytochrome c release. However, the levels of the pro-apop-
totic proteins BIM, PUMA, BMF and BAX did not increase,
and the levels of the anti-apoptotic proteins MCL-1, BCL-
XL and BCL-2 did not decrease. It should be pointed out
that DIDS, a VDAC inhibitor, inhibited PK11195-induced
apoptosis, suggesting an involvement of VDAC.
Significantly, VDAC has been proposed as one of the com-
ponents of the permeability transition pore complex
(PTPC) that mediates cytochrome c release.40 Additionally,
VDAC interacts and modulates or is modulated by BCL-2
family members such as BCL-2, BCL-XL, BAX, BAK, and
BIM.42-44 BAX and BAK may co-operate with the PTPC to
form a channel, but whether cytochrome c release is main-
ly mediated by the PTPC and/or the pore-forming function
of BAX/BAK is still open to debate.42,43 Thus, the mecha-
nism by which PK11195 induces cytochrome c release
requires further investigation using cells lines in which the
candidate proteins could be down-regulated efficiently. 
Our experiments indicate that CLL cells and normal B
cells are more sensitive to PK11195-, RO 5-4864-, and
FGIN-1-27-induced apoptosis than are T cells from the
same samples. Chemotherapeutic drugs including fludara-
bine, chlorambucil, and doxorubicin induce apoptosis
equally in both B and T cells5,45 leading to immunosuppres-
sion.46 Thus, the differential effect of PK11195 in B and T
lymphocytes is of interest.  Most drugs currently used in
the therapy of CLL act, at least partially, through activation
of the p53 pathway.2,5-7 p53 is mutated in 5-10% of CLL
cases at diagnosis, but in nearly 30% of chemotherapy-
resistant tumors.2-4,8 Furthermore, ATM is inactivated in 10-
20% of CLL cases thus providing an alternative way for
disabling p53 function.47,48 Tumors with alterations
upstream of p53 would not respond adequately to geno-
toxic chemotherapeutics that act through the p53 path-
way, for example, alkylating agents (chlorambucil,
cyclophosphamide), purine nucleosides (fludarabine,
cladribine) or topoisomerase inhibitors (doxorubicin,
mitoxantrone). Genetic alterations in P53 and ATM are
among the worst prognostic factors in CLL patients,3,4,46-49
and p53 alterations confer resistance to conventional
chemotherapy.3,4,7 Thus, new approaches to induce apopto-
sis in cells with mutated p53 or ATM are needed. Here, we
demonstrate that PK11195 induces apoptosis in CLL cells
irrespectively of their p53 or ATM status. 
From a therapeutic perspective, it is interesting to note
that the doses of PK11195 that induce apoptosis in CLL
samples in vitro are achievable in vivo, as previously demon-
strated by their potent antitumor effect in mouse models
of human cancer.11,21,50 PK11195 has been administered safe-
ly to patients.51,52 Furthermore, PK11195 has additive
effects with chemotherapeutic drugs in CLL. This suggests
that it could be possible to lower the doses of chemother-
apeutic drugs used in the treatment of CLL and thus reduce
cytotoxicity to normal T cells. In conclusion, the results
presented here suggest that PK11195 alone or in combina-
tion with chemotherapeutic drugs might be a new thera-
peutic option for the treatment of CLL. 
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